Modern management of MS targets No Evidence of Disease Activity (NEDA): no clinical
relapses, no magnetic resonance imaging (MRI) disease activity and no disability …

Gadolinium-based contrast agents (GBCAs) are used in up to 35% of magnetic resonance
imaging (MRI) examinations and are associated with an excellent safety profile …

MRI plays a crucial role in multiple sclerosis diagnostic and patient follow-up. In particular,
the delineation of T2-FLAIR hyperintense lesions is crucial although mostly performed …

A biomarker-enhanced monitoring strategy has immediate clinical application, with growing
evidence of long-term reductions in disability accrual when both clinically symptomatic and …

Background and Objectives To estimate the proportions of patients with relapsing-remitting
multiple sclerosis who despite achieving the no evidence of disease activity-3 (NEDA-3) …

Different types of white matter hyperintensities (WMH) can be observed through MRI in the
brain and spinal cord, especially Multiple Sclerosis (MS) lesions for patients suffering from …

Objectives The development of new drugs for the treatment of progressive multiple sclerosis
(MS) highlights the need for new prognostic biomarkers. Phase-rim lesions (PRLs) have …

Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system
(CNS) affecting more than half a million persons in Europe, with a prevalence rate of 83 per …

Over the last 10 years, the number of approved disease modifying drugs acting on the focal
inflammatory process in Multiple Sclerosis (MS) has increased from 3 to 10. This wide …

Gadolinium-based contrast agents have been used in hundreds of millions of patients in the
past 30 years, with an exemplary safety record. However, assumptions made at their …